| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 8,290 | 5,100 | 1,400 | 12,260 | 26,050 |
| Sales Growth | +62.55% | +264.29% | -88.58% | -52.94% | -27.05% |
| Net Income | -108,910 | -61,370 | -54,250 | -79,770 | -208,750 |
| Net Income Growth | -77.46% | -13.12% | +31.99% | +61.79% | -41.93% |
Kadmon Holdings Llc
(KDMN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kadmon Holdings Inc. is a biopharmaceutical company. It discovers, develops and delivers transformative therapies for unmet medical needs. The company's product pipeline includes KD025, KD045 and KD033 which are in clinical satge. Kadmon Holdings Inc. is based in New York.
Fiscal Year End Date: 12/31